Marker Therapeutics Reports Year-End 2023 Corporate and
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant...
Source: globenewswire.com
Pre Clinical Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pre Clinical Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pre Clinical Data Today - Breaking & Trending Today
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
Source: marketscreener.com
Marker Therapeutics Announces Clinical Program Updates and
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical...
Source: globenewswire.com
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...
Source: marketscreener.com
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong... | May 11, 2023
Source: marketscreener.com